Samrat Pharmachem Limited has submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 to BSE Limited. The pharmaceutical chemicals manufacturer filed the mandatory Certificate under Regulation 74(5) for the quarter ended March 31, 2026, demonstrating adherence to regulatory requirements.

Regulatory Compliance Details

The certificate was issued by MUFG Intime India Private Limited, the company's registrar and transfer agent, and subsequently submitted to BSE Limited on April 7, 2026. Company Secretary and Compliance Officer Nishant Kankaria signed the submission letter, ensuring proper corporate governance protocols were followed.

Certificate Confirmation

MUFG Intime India Private Limited confirmed that all securities received from depository participants for dematerialisation during Q4FY26 were properly processed within prescribed timelines. The registrar verified that security certificates received for dematerialisation were confirmed or rejected appropriately, with physical certificates being mutilated and cancelled after due verification.

Corporate Information

Samrat Pharmachem Limited operates as a manufacturer and exporter of pharmaceutical chemicals. The company maintains its registered office and factory at Plot No. A2/3444-3445, GIDC, Phase 4, Ankleshwar, Gujarat, while its corporate office is located in Mumbai. The company's CIN is L24230GJ1992PLC017820.

Compliance Framework

The submission fulfills SEBI's requirement for listed companies to provide quarterly certificates confirming proper handling of dematerialisation processes. This regulatory framework ensures transparency in securities handling and maintains investor confidence in the dematerialisation system. The certificate confirms that the company's registrar has substituted depository names in the register of members as registered owners within prescribed timelines.

Samrat Pharmachem Limited has announced a credit rating upgrade from Crisil Limited, marking a positive development for the pharmaceutical chemicals manufacturer and exporter. The company disclosed this information in compliance with regulatory requirements under SEBI listing obligations.

Credit Rating Enhancement Details

Crisil Limited has revised its assessment of Samrat Pharmachem Limited's creditworthiness, upgrading the rating on the company's bank facilities. The rating agency has moved the company's credit profile from a negative outlook to a stable outlook.

Regulatory Compliance and Disclosure

The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Company Secretary and Compliance Officer Nishant Kankaria signed the disclosure document, ensuring proper regulatory compliance.

The company has made this information publicly available on its official website at www.samratpharmachem.com , providing transparency to all stakeholders including investors, creditors, and business partners.

Company Background

Samrat Pharmachem Limited operates as a manufacturer and exporter of pharmaceutical chemicals, with its registered office and factory located at GIDC Phase 4, Ankleshwar, Gujarat. The company maintains its corporate office in Andheri West, Mumbai, serving as the operational hub for its business activities.

The credit rating upgrade reflects the rating agency's assessment of the company's financial position and creditworthiness, which could potentially impact the company's borrowing costs and access to credit facilities from banking institutions.